

Recombinant Human CD80/B7-1 Protein

Catalog Number:PKSH031476



Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

| | |
|------------------------------------|---|
| Synonyms | CD80;Activation B7-1 antigen;B7;BB1;CD28LG1;CD28LGB7-1 antigen;T-lymphocyte activation antigen CD80;B7-1;B7.1;CD28LG;LAB7 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Asn 242 |
| Accession | NP_005182.1 |
| Calculated Molecular Weight | 25.5 kDa |
| Tag | None |

Properties

| | |
|-----------------------|---|
| Purity | > 85 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per µg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |

Data



> 85 % as determined by reducing SDS-PAGE.

Background

The B-lymphocyte activation antigen B7-1 (referred to as B7); also known as CD80; is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells; macrophages and dendritic cells. As costimulatory ligands; B7-1 which exists predominantly as dimer and the related protein B7-2; interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells; and thus constitute one of the dominant pathways that regulate T cell activation and tolerance; cytokine production; and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

For Research Use Only

A Reliable Research Partner in Life Science and Medicine

Toll-free: 1-888-852-8623

Web: www.elabscience.com

Tel: 1-832-243-6086

Email: techsupport@elabscience.com

Fax: 1-832-243-6017